FGFR2 and cholangiocarcinoma: In FGFR2-altered cholangiocarcinoma, clinical sequencing at progression frequently reveals polyclonal secondary FGFR2 mutations and pathway rewiring, limiting the durability of FGFR inhibitors [16].